FTSE MIB
33.643,78 +335,01 (+1,01%) Dow Jones
39.150,33 +15,53 (+0,04%) Nasdaq
17.689,36 -32,24 (-0,18%) Nikkei 225
38.804,65 +208,18 (+0,54%) Petrolio
80,74 +0,01 (+0,01%) Bitcoin EUR
56.875,92 -3.051,54 (-5,09%)
BAX Jun 2024 42.000 call
| Chiusura precedente | 0,0500 |
| Aperto | N/D |
| Denaro | 0,0000 |
| Domanda | 2,1500 |
| Prezzo d'esercizio | 42,00 |
| Scadenza | 2024-06-21 |
| Min-Max giorno | 0,0500 - 0,0500 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 52 |
GlobeNewswireCORRECTION – Spectral Medical Inc. Closes C$6.1 Million Bought Deal Convertible Note Financing
Tigris patient enrollment momentum continues reaching 72 The Company anticipates three additional trial sites to be activated in Q3 NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CORRECTION FROM SOURCE: Spectral Medical Inc. A correction from source is being issued with respect to the press release titled, Spectral Medical Inc. Closes C$6.1 Million Bought Deal Convertible Note Financing, released on September 7, 2023, at 7:00 am ET. There was an
- GlobeNewswire
Spectral Medical Inc. Closes C$6.1 Million Bought Deal Convertible Note Financing
Tigris patient enrollment momentum continues reaching 72 The Company anticipates three additional trial sites to be activated in Q3 NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce that it has closed its previously announced ”bought deal” private placement of 9.0% convertible unsecured senior notes due November 1, 2026
